We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation |

Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal:  A Randomized Clinical Trial

David J. Allsop, PhD1,2; Jan Copeland, PhD1; Nicholas Lintzeris, PhD3,4; Adrian J. Dunlop, PhD5,6; Mark Montebello, FAChAM3; Craig Sadler, FAChAM5; Gonzalo R. Rivas, BNurs3; Rohan M. Holland, BNurs5; Peter Muhleisen, BPharm, MPSA5; Melissa M. Norberg, PhD1,7; Jessica Booth, BSc (Hons)8; Iain S. McGregor, PhD8
[+] Author Affiliations
1National Cannabis Prevention and Information Centre, National Drug and Alcohol Research Centre, Faculty of Medicine, University of New South Wales, Sydney, Australia
2now with the School of Psychology, University of Sydney, Sydney, Australia
3Drug and Alcohol Services, South Eastern Sydney Local Health District New South Wales Ministry of Health, Sydney, Australia
4Addiction Medicine, Central Clinical School, Faculty of Medicine, University of Sydney, Sydney, Australia
5Drug and Alcohol Clinical Services, Hunter New England Local Health District, New South Wales Ministry of Health, Newcastle, Australia
6School of Medicine and Public Health, Faculty of Health, University of Newcastle, Newcastle, Australia
7Department of Psychology, Macquarie University, Sydney, Australia
8School of Psychology, University of Sydney, Sydney, Australia
JAMA Psychiatry. 2014;71(3):281-291. doi:10.1001/jamapsychiatry.2013.3947.
Text Size: A A A
Published online

Importance  There are no medications approved for treating cannabis dependence or withdrawal. The cannabis extract nabiximols (Sativex), developed as a multiple sclerosis treatment, offers a potential agonist medication for cannabis withdrawal.

Objective  To evaluate the safety and efficacy of nabiximols in treating cannabis withdrawal.

Design, Setting, and Participants  A 2-site, double-blind randomized clinical inpatient trial with a 28-day follow-up was conducted in New South Wales, Australia. Participants included 51 DSM-IV-TR cannabis-dependent treatment seekers.

Interventions  A 6-day regimen of nabiximols (maximum daily dose, 86.4 mg of Δ9-tetrahydrocannabinol and 80 mg of cannabidiol) or placebo with standardized psychosocial interventions during a 9-day admission.

Main Outcomes and Measures  Severity of cannabis withdrawal and cravings (Cannabis Withdrawal Scale), retention in withdrawal treatment, and adverse events. Secondary outcomes include postwithdrawal cannabis use, health outcomes, and psychosocial outcomes.

Results  Nabiximols treatment significantly reduced the overall severity of cannabis withdrawal relative to placebo (F8,377.97 = 2.39; P = .01), including effects on withdrawal-related irritability, depression, and cannabis cravings. Nabiximols had a more limited, but still positive, therapeutic benefit on sleep disturbance, anxiety, appetite loss, physical symptoms, and restlessness. Nabiximols patients remained in treatment longer during medication use (unadjusted hazard ratio, 3.66 [95% CI, 1.18-11.37]; P = .02), with 2.84 the number needed to treat to achieve successful retention in treatment. Participants could not reliably differentiate between nabiximols and placebo treatment (χ21 = 0.79; P = .67), and those receiving nabiximols did not report greater intoxication (F1,6 = 0.22; P = .97). The number (F1,50 = 0.3; P = .59) and severity (F1,50 = 2.69; P = .10) of adverse events did not differ significantly between groups. Both groups showed reduced cannabis use at follow-up, with no advantage of nabiximols over placebo for self-reported cannabis use (F1,48 = 0.29; P = .75), cannabis-related problems (F1,49 = 2.33; P = .14), or cannabis dependence (F1,50 < 0.01; P = .89).

Conclusions and Relevance  In a treatment-seeking cohort, nabiximols attenuated cannabis withdrawal symptoms and improved patient retention in treatment. However, placebo was as effective as nabiximols in promoting long-term reductions in cannabis use following medication cessation. The data support further evaluation of nabiximols for management of cannabis dependence and withdrawal in treatment-seeking populations.

Trial Registration  anzctr.org.au Identifier: ACTRN12611000398909

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal


Place holder to copy figure label and caption
Figure 1.
Study Flow

Diagram shows the number of participants at each stage of the study.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Mean Change From Baseline in Withdrawal Score for Overall Withdrawal Scores and for Symptoms That Were Significantly Suppressed by Nabiximols

The adjusted model graphs show the mean values across all 5 multiply imputed data sets. Effect sizes (Hedges g) for change in withdrawal scores each day relative to baseline are reported. Sample sizes in each treatment arm before multiple imputation are also shown. Significance was based on the unadjusted mixed models for repeated measures (MMRM) post hoc pairwise comparisons between groups on each day, adjusted for multiple comparisons using Bonferroni adjustment. Treatment × time interactions shown: Omnibus type II test of fixed effects from adjusted MMRM. Error bars indicate standard error.aP ≤ .01.bP ≤ .05.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.
Retention in Withdrawal Treatment

The 2 hazard ratios (HRs) determined from the Cox regression marked on the graph show retention estimates at 2 time points: The day 6 HR (4.09) was computed with all remaining patients censored at day 6 to assess the effect of treatment allocation on retention during the medication administration phase. The day 9 HR (1.5) was computed with all remaining patients censored at day 9 to assess the overall effect of treatment allocation on retention, including the 3-day postmedication washout period.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 4

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles